Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02062125 · ClinicalTrials.gov registry record
Calcinosis in a Single-Center Scleroderma Population
A clinical trial of Scleroderma and Calcinosis, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- 66
- Enrollment target
- 1
- Study location
NCT02062125: Completed study of Scleroderma and Calcinosis, sponsored by Rutgers, The State University of New Jersey.
NCT02062125 is a study of Scleroderma and Calcinosis that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 66 participants, below the 400-participant average among 23 other Scleroderma trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02062125, a study of Scleroderma and Calcinosis, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- 66 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 10 year study of scleroderma patients with calcinosis 1) to better understand how common and if there are any risk factors for having calcinosis 2\) to identify common complications associated with scleroderma-related calcinosis. .
Primary Outcome
This is an observational study of scleroderma calcinosis to assess possible risk factors (including serologic studies and disease types) as well as common complications that occur in those with scleroderma calcinosis during this time period. We will assess for increased burden of calcinosis with associated musculoskeletal complications from calcinosis over 10 years. No additional intervention will be delivered, other than standard of care for this complication.
Conditions Studied
Study Locations (1)
New Jersey
- RWJ Medical School - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2012-10-31 |
| Est. Completion | 2024-03-15 |
What the finished NCT02062125 record still lists
NCT02062125 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 400-participant average among 23 other Scleroderma trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Scleroderma appearing as the primary indexed condition, and to 0 interventions.
NCT02062125 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT02062125 about?
NCT02062125 is a clinical study titled "Calcinosis in a Single-Center Scleroderma Population". This is a 10 year study of scleroderma patients with calcinosis 1) to better understand how common and if there are any risk factors for having calcinosis 2\) to identify common complications associated with scleroderma-related calcinosis. .
What is the current status of trial NCT02062125?
This trial is currently completed. The enrollment target is 66 participants. The study started on 2012-10-31. Estimated completion is 2024-03-15.
What conditions does trial NCT02062125 study?
This clinical trial studies the following conditions: Scleroderma, Calcinosis.
Who is sponsoring clinical trial NCT02062125?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02062125 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scleroderma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02062125's enrollment target sits among peer trials
66 14th of 23 higher than 9 of 23 other Scleroderma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Scleroderma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rheumatology Diet Study
RECRUITING
-
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RECRUITING
-
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RECRUITING · Phase 1
-
Platform Clinical Study for Conquering Scleroderma
RECRUITING · Phase 2
-
Scleroderma Registry & Repository at the Hospital for Special Surgery
RECRUITING
-
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI